Well established screening programmes for early detection of carcinoma cervix are present in developed countries which are contrary to scenario in developing countries like India. Present study was aimed to study diagnostic efficacy of visual inspection with acetic acid (VIA) in comparison with PAP smear in cervical cancer screening. Present study was single‐center, prospective, comparative, observational study, conducted female over 19 years of age, married and gave valid consent for examination All subjects were screened simultaneously by Pap smear and VIA. Among 500 patients, 99 patients had ace to white lesions and 401 patients did not have ace to white lesions. Among 500 patients who underwent pap smear testing, 455 patients were negative for intra epithelial lesion, 7 patients had ASCUS, 2 patients had ASC‐H, 17 patients had LSIL, 17 patients had HSIL and 2 patients had squamous cell carcinoma. Out of 500 patients, 99 of them had ace to white lesions on VIA, 45 were reported to have lesions on pap smear, 19 were lesions on both pap smear and VIA. Hence biopsy was done. Rest 375 patients did not have ace to white lesions on VIA and Pap smear also was negative was intra epithelial lesion. So, biopsy was done. Out of 500 patients, biopsy was done in 125 patients where 67 patients were negative for dysplasia, 36 patients had CIN 1, 6 patients had CIN 2, 14 patients had CIN 3 and 2 patients had squamous cell carcinoma. In this study VIA had sensitivity 89.65%, specificity 89.36%, PPV 52.5% and NPV 98.5% while Pap smear had sensitivity 41%, specificity 95.7%, PPV 53.33% and NPV 90.96%. VIA should be considered as a screening modality especially in a low resource setting and be implemented as a large‐scale screening method.
Nisha Buchade and Rahul S. Kanaka. Study of Diagnostic Efficacy of Visual Inspection with Acetic Acid (VIA) in Comparison with PAP Smear in Cervical Cancer Screening.
DOI: https://doi.org/10.36478/10.36478/makrjms.2024.11.336.340
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2024.11.336.340